AR and Familial prostate cancer: Likewise, in prostate cancer, the de novo biosynthesis of androgens from cholesterol activates androgen receptor (AR) activity in castration resistant disease (99), thus suggesting a role for the MVA pathway in prostate cancer progression, also considering the observations that SREBP expression is enhanced in advanced stages of prostate cancer.